FIG. 1.

AAV5-based cytomegalovirus (CMV) lacZ was derived from plasmid pAAV5 Rn (6), while the AAV5 packaging construct pack 5 was derived from viral AAV5 DNA (3). The hybrid packaging construct pack 2/5 was created by exchanging AAV2 cap from the AAV2 packaging construct p600 trans (2) with AAV5 cap. The AAV2-based AAV CMV lacZ construct has been described previously (2). (A) Transduction of murine muscle with AAV5 CMV lacZ. The right anterior tibialis of C57BL/6 mice was injected with 10¹⁰ genome copies of AAV5 CMV lacZ and harvested 28 days postinjection. (B) Higher magnification of panel A. (C and D) Transduction of murine muscle with AAV2/5 CMV lacZ (C) and AAV2 CMV lacZ (D). The right anterior tibialis muscle of C57BL/6 mice was injected with 4 × 10¹⁰ genome copies of AAV2/5 CMV lacZ and AAV2 CMV lacZ, respectively. Muscles were harvested 60 days postinjection. (E) Transduction of murine smooth muscle with AAV2/5 CMV lacZ. We injected 10¹⁰ genome copies of AAV2/5 CMV lacZ subcutaneously into C57BL/6 mice. Expression of β-gal was assessed 60 days after vector administration. (F) Higher magnification of panel E. (G and H) Apical transduction of primary human epithelial airway cells with AAV2/5 (G) and AAV2CMV (H). Primary human airway epithelial cells were infected apically with 5 × 10¹⁰ genomic particles of the corresponding virus (liquid-air transwell system). Cells were fixed and stained with 5-bromo-4-chloro-3-indolyl-β-d-galactopyranoside (X-Gal) 7 days postinfection.